Stock analysts at StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV – Get Rating) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.
ObsEva Price Performance
Shares of NASDAQ:OBSV opened at $0.08 on Friday. ObsEva has a 12 month low of $0.08 and a 12 month high of $2.14. The stock has a market cap of $6.55 million, a price-to-earnings ratio of -0.09 and a beta of 0.68. The stock’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.15.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in OBSV. Credit Suisse AG lifted its stake in ObsEva by 11.0% during the fourth quarter. Credit Suisse AG now owns 1,750,573 shares of the company’s stock valued at $255,000 after buying an additional 173,455 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of ObsEva in the third quarter valued at $25,000. Pictet Asset Management SA lifted its holdings in shares of ObsEva by 25.8% in the third quarter. Pictet Asset Management SA now owns 371,595 shares of the company’s stock valued at $53,000 after purchasing an additional 76,196 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of ObsEva in the second quarter valued at $192,000. Finally, Bank of America Corp DE lifted its holdings in shares of ObsEva by 54,142.2% in the first quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock valued at $731,000 after purchasing an additional 483,490 shares in the last quarter. Institutional investors and hedge funds own 17.52% of the company’s stock.
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
- Get a free copy of the StockNews.com research report on ObsEva (OBSV)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.